Post by
Noteable on Jan 28, 2024 4:54pm
Pelareorep I/O capacity uneffected x neutralizing antibodies
NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity (confirming pelareorep's effectiveness in combination with immune checkpoint inhibitors and other T cell engagers).
https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-23-0480/733034/Neutralizing-antibodies-impair-the-oncolytic
Comment by
Noteable on Jan 28, 2024 5:15pm
" ... data strongly advocate(s) for the application of Reo as part of T cell–based immunotherapeutic strategies."
Comment by
Noteable on Feb 05, 2024 9:17pm
And as reported by ONCY, NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity (confirming pelareorep's effectiveness in combination with immune checkpoint inhibitors and other T cell engagers). https://aacrjournals.org/cancerimmunolres/article/doi/10.1158/2326-6066.CIR-23-0480/733034/Neutralizing-antibodies-impair-the-oncolytic